Compass Therapeutics (CMPX) Equity Average (2023 - 2025)
Historic Equity Average for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $151.4 million.
- Compass Therapeutics' Equity Average rose 643.86% to $151.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 643.86%. This contributed to the annual value of $136.9 million for FY2024, which is N/A changed from last year.
- According to the latest figures from Q3 2025, Compass Therapeutics' Equity Average is $151.4 million, which was up 643.86% from $101.7 million recorded in Q2 2025.
- Compass Therapeutics' 5-year Equity Average high stood at $171.8 million for Q2 2023, and its period low was $101.7 million during Q2 2025.
- In the last 3 years, Compass Therapeutics' Equity Average had a median value of $151.5 million in 2024 and averaged $144.0 million.
- Data for Compass Therapeutics' Equity Average shows a peak YoY increase of 643.86% (in 2025) and a maximum YoY decrease of 3287.92% (in 2025) over the last 5 years.
- Compass Therapeutics' Equity Average (Quarter) stood at $154.3 million in 2023, then dropped by 14.57% to $131.8 million in 2024, then increased by 14.87% to $151.4 million in 2025.
- Its Equity Average was $151.4 million in Q3 2025, compared to $101.7 million in Q2 2025 and $117.8 million in Q1 2025.